JP2024528731A - 眼癌転移を予防するためのイブジラスト - Google Patents

眼癌転移を予防するためのイブジラスト Download PDF

Info

Publication number
JP2024528731A
JP2024528731A JP2024505211A JP2024505211A JP2024528731A JP 2024528731 A JP2024528731 A JP 2024528731A JP 2024505211 A JP2024505211 A JP 2024505211A JP 2024505211 A JP2024505211 A JP 2024505211A JP 2024528731 A JP2024528731 A JP 2024528731A
Authority
JP
Japan
Prior art keywords
day
ibudilast
cancer
acceptable salt
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528731A5 (enExample
Inventor
和子 松田
アンブロジーニ，グラツィア
ケー． シュヴァルツ，ゲーリー
ジェイ． ライ，アレックス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of JP2024528731A publication Critical patent/JP2024528731A/ja
Publication of JP2024528731A5 publication Critical patent/JP2024528731A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024505211A 2021-07-26 2022-07-25 眼癌転移を予防するためのイブジラスト Pending JP2024528731A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225820P 2021-07-26 2021-07-26
US63/225,820 2021-07-26
PCT/US2022/038157 WO2023009425A1 (en) 2021-07-26 2022-07-25 Ibudilast for preventing eye cancer metastasis

Publications (2)

Publication Number Publication Date
JP2024528731A true JP2024528731A (ja) 2024-07-30
JP2024528731A5 JP2024528731A5 (enExample) 2025-07-31

Family

ID=82851760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505211A Pending JP2024528731A (ja) 2021-07-26 2022-07-25 眼癌転移を予防するためのイブジラスト

Country Status (6)

Country Link
US (1) US12005049B2 (enExample)
EP (1) EP4376838B1 (enExample)
JP (1) JP2024528731A (enExample)
CN (1) CN117940128A (enExample)
CA (1) CA3226898A1 (enExample)
WO (1) WO2023009425A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024528731A (ja) 2021-07-26 2024-07-30 メディシノバ・インコーポレイテッド 眼癌転移を予防するためのイブジラスト
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8562198A (en) 1998-08-10 2000-03-06 Kyorin Pharmaceutical Co. Ltd. Remedies for multiple sclerosis
WO2006063048A2 (en) 2004-12-06 2006-06-15 Avigen, Inc. Ibudilast for treating neuropathic pain and associated syndromes
CA2693697C (en) 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
US20150157584A1 (en) * 2012-06-11 2015-06-11 The J. David Gladstone Institutes Inhibitors of hippo-yap signaling pathway
US10258611B2 (en) 2014-11-26 2019-04-16 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
EP3558301A4 (en) 2016-12-22 2020-07-29 MediciNova, Inc. METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST
CA3090884A1 (en) 2018-02-12 2019-08-15 Medicinova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy
CA3090887A1 (en) 2018-02-12 2019-08-15 Medicinova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients
EP3863628B1 (en) 2018-10-09 2023-12-27 MediciNova, Inc. Combination of ibudilast and interferon-beta and methods of using same
ES2970996T3 (es) 2018-10-19 2024-06-03 Medicinova Inc Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast
JP7652763B2 (ja) 2019-09-23 2025-03-27 メディシノバ・インコーポレイテッド イブジラスト経口製剤およびその使用方法
CN115335049A (zh) 2020-04-06 2022-11-11 美迪诺亚公司 降低患者中巨噬细胞迁移抑制因子的血浆水平的方法
CN116887829A (zh) 2021-01-29 2023-10-13 美迪诺亚公司 治疗化学气体暴露的方法
JP2024528731A (ja) 2021-07-26 2024-07-30 メディシノバ・インコーポレイテッド 眼癌転移を予防するためのイブジラスト
CA3231869A1 (en) 2021-09-21 2023-03-30 Medicinova, Inc. Ibudilast in combination therapy for use in the treatment of glioblastoma
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
JP2025504984A (ja) 2022-02-01 2025-02-19 メディシノバ・インコーポレイテッド Ｃｏｖｉｄ後症状の治療における使用のためのイブジラスト

Also Published As

Publication number Publication date
EP4376838B1 (en) 2026-08-12
US20230037014A1 (en) 2023-02-02
US12005049B2 (en) 2024-06-11
CN117940128A (zh) 2024-04-26
CA3226898A1 (en) 2023-02-02
WO2023009425A1 (en) 2023-02-02
EP4376838A1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
EP2913047B1 (en) Pulmonary disease-specific therapeutic agent
JP2025020319A (ja) テルリプレシン組成物およびその使用方法
JP2020504721A (ja) イブジラストを使用した多形膠芽腫の治療方法
US12005049B2 (en) Methods of preventing cancer metastasis
ES2959799T3 (es) Métodos para suprimir células supresoras de origen mieloide en pacientes
JP7652763B2 (ja) イブジラスト経口製剤およびその使用方法
US12171752B2 (en) Methods of treating post-COVID condition(s)
JP2023529764A (ja) 下気道障害の処置
JP2024535880A (ja) 膠芽腫の治療における使用のための併用療法におけるイブジラスト
US20220241252A1 (en) Methods of treating chemical gas exposure
US12042485B2 (en) Methods of minimizing cancer metastasis
JP2022504435A (ja) イブジラストとインターフェロン－ベータとの組み合わせ、およびそれを使用する方法
JP2024517694A (ja) インターロイキン－１受容体アンタゴニストの組成物
HK40014065B (en) Terlipressin composition for use in treating ascites
HK40014065A (en) Terlipressin composition for use in treating ascites

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250723

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260804